Compound: benserazide
SMILES: O=C(NNCc1c(O)c(O)c(O)cc1)C(N)CO
InChIKey: BNQDCRGUHNALGH-UHFFFAOYSA-N
Synonyms: benserazide, 322-35-0, Serazide, Benserazida, Ro 4-4602, Benserazidum, DL-Serine 2-(2,3,4-trihydroxybenzyl)hydrazide, Ro 44602, DL-Serine, 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide, DL-Seryltrihydroxybenzylhydrazine, 2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide, 762OS3ZEJU, DTXSID9022651, 2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide, Ro-4-4602, Benserazide (as hydrochloride), DL-Serine 2-((2,3,4-trihydroxyphenyl)methyl)hydrazide, CHEBI:64187, MADOPAR COMPONENT BENSERAZIDE, PROLOPA COMPONENT BENSERAZIDE, NSC-755907, DL-serine 2-[(2,3,4-trihydroxyphenyl)methyl]hydrazide, Seryltrihydroxybenzylhydrazine, Seryltrihydroxy Benzylhydrazine, Benzylhydrazine, Seryltrihydroxy, 2-amino-3-hydroxy-N'-((2,3,4-trihydroxyphenyl)methyl)propanehydrazide, Ro 4 4602, RefChem:561256, DTXCID302651, Benserazidum [INN-Latin], Benserazida [INN-Spanish], Benserazide [USAN:INN:BAN], UNII-762OS3ZEJU, BRN 3984490, benserazid a, component of Madopa, Spectrum_000070, BENSERAZIDE [MI], Prestwick0_000938, Prestwick1_000938, Prestwick2_000938, Prestwick3_000938, Spectrum2_000140, Spectrum3_000312, Spectrum4_000247, Spectrum5_000856, BENSERAZIDE [INN], Benserazide (USAN/INN), BENSERAZIDE [USAN], BENSERAZIDE [MART.], Lopac0_000233, SCHEMBL34522, BENSERAZIDE [WHO-DD], BSPBio_000876, BSPBio_001904, KBioGR_000654, KBioSS_000470, cid_26964, Serine, 2-(2,3,4-trihydroxybenzyl)hyrazide, DL-, DivK1c_000469, SPBio_000220, SPBio_003045, BPBio1_000964, GTPL5150, orb1707354, CHEMBL1096979, SCHEMBL29401071, BDBM49122, KBio1_000469, KBio2_000470, KBio2_003038, KBio2_005606, KBio3_001404, NINDS_000469, GLXC-05408, HMS2089P07, ALBB-028956, EBC-26345, STL483707, AKOS015960744, CCG-204328, DB12783, SDCCGSBI-0050221.P005, IDI1_000469, NCGC00015163-03, NCGC00015163-04, NCGC00015163-06, NCGC00015163-08, NCGC00015163-17, NCGC00089783-02, AC-12038, DL-Seryl 2,3,4-trihydroxybenzylhydrazine, SBI-0050221.P004, HY-121275, AB00053423, CS-0081350, NS00009834, D03082, AB00053423-13, AB00053423-14, AB00053423_15, AB00053423_16, EN300-26189428, Q818165, Serine, 2-(2,3,4-trihydroxybenzyl)hydrazide, dl-, BRD-A61194565-003-14-8, BRD-A61194565-003-27-0, BRD-A61194565-003-28-8, 2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanohydrazide, 2-Amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanohydrazide #, 2-amino-3-hydroxy-N''-(2,3,4-trihydroxybenzyl)propionohydrazide;hydrochloride, 2-amino-3-hydroxy-N''-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide;hydrochloride, 2-amino-3-hydroxy-N'-(2,3,4-trihydroxybenzyl)propanehydrazide (non-preferred name), 2-azanyl-3-oxidanyl-N''-[[2,3,4-tris(oxidanyl)phenyl]methyl]propanehydrazide;hydrochloride
Theoretical properties:
molecular_formula: C10H15N3O5
molecular_weight: 257.24 g/mol
exact_mass: 257.10117059 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 7
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 5
heavy_atom_count: 18
topological_polar_surface_area: 148 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": "Benserazide is a carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone. It has a role as an antiparkinson drug, a dopaminergic agent and an EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor. It is a primary alcohol, a member of catechols, a carbohydrazide and a primary amino compound. It is a conjugate base of a benserazide(1+).", "chebi": "A carbohydrazide that results from the formal condensation of the carboxy group of <small>D</small><small>L</small>-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-<small>L</small>-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.", "chembl": "BENSERAZIDE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 3.0.", "wikipedia": "Benserazide is a peripherally acting aromatic L-amino acid decarboxylase or DOPA decarboxylase inhibitor, which is unable to cross the blood\u2013brain barrier.\nBenserazide is a therapeutic alternative on the World Health Organization's List of Essential Medicines."}